Eli Lilly and Company

What does Eli Lilly make?
Eli Lilly makes prescription pharmaceuticals across several therapeutic areas. Its most important products are Mounjaro (tirzepatide for type 2 diabetes) and Zepbound (tirzepatide for obesity), which are dual GIP/GLP-1 receptor agonists. The company also makes Verzenio (breast cancer), Trulicity (diabetes), Taltz (psoriasis), Humalog (insulin), and Emgality (migraine).

Is Eli Lilly publicly traded?
Yes, Eli Lilly and Company is listed on NYSE under ticker LLY. Major institutional shareholders include Vanguard Group, BlackRock, and State Street.

Who founded Eli Lilly?
Eli Lilly was founded in 1876 in Indianapolis, Indiana by Colonel Eli Lilly, a Civil War veteran and pharmacist. The company made its first major breakthrough in 1923 when it produced commercial quantities of insulin.

Where is Eli Lilly headquartered?
Eli Lilly is headquartered in Indianapolis, Indiana, USA, where the company was founded in 1876. The company operates research and development centers, manufacturing facilities, and commercial operations in more than 120 countries.

What is Mounjaro and Zepbound?
Mounjaro and Zepbound both contain tirzepatide, a dual GIP/GLP-1 receptor agonist developed by Eli Lilly. Mounjaro is approved for type 2 diabetes, while Zepbound is approved for obesity. Tirzepatide has demonstrated superior efficacy to existing GLP-1 drugs in clinical trials, with patients losing an average of approximately 20% of their body weight in obesity trials.

Who owns Eli Lilly?
Eli Lilly and Company is publicly traded on NYSE with a broad institutional and retail shareholder base. No single shareholder holds a controlling stake. David Ricks serves as Chairman and CEO.

Eli Lilly and Company was founded in 1876 in Indianapolis, Indiana by Colonel Eli Lilly, a Civil War veteran and pharmacist. Lilly was dissatisfied with the poor quality of medicines available at the time and established his company to produce pharmaceutical products of consistent quality and purity.

Eli Lilly made its first major scientific breakthrough in 1923, when the company partnered with University of Toronto researchers to produce commercial quantities of insulin for the treatment of diabetes. This saved countless lives and established Eli Lilly as a leader in diabetes care, a position it has maintained for more than a century.

The company developed numerous important pharmaceutical products through the 20th century, including Darvon (a pain reliever), Seconal (a sedative), and Keflex (an antibiotic). Eli Lilly also produced the first commercial quantities of penicillin during World War II.

Eli Lilly launched Prozac (fluoxetine) in 1988, which became one of the best-selling antidepressants in history. Prozac generated billions of dollars in revenue for Eli Lilly through the 1990s and early 2000s.

The company launched Zyprexa (olanzapine) for schizophrenia in 1996 and Cymbalta (duloxetine) for depression in 2004, both major commercial products. Eli Lilly entered the GLP-1 receptor agonist market with Trulicity (dulaglutide) for type 2 diabetes in 2014.

The company received FDA approval for Mounjaro (tirzepatide) for type 2 diabetes in May 2022 and for Zepbound (tirzepatide) for obesity in November 2023. Tirzepatide, a dual GIP/GLP-1 receptor agonist, demonstrated superior efficacy to existing GLP-1 drugs in clinical trials, with patients losing an average of approximately 20% of their body weight in obesity trials. The commercial launch of Mounjaro and Zepbound drove explosive revenue growth, with Eli Lilly's annual revenue growing from approximately $28 billion in 2022 to approximately $45 billion in 2024.